CLINICAL TRIALS PROFILE FOR OCREVUS

All Clinical Trials for OCREVUS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01466114 ↗	Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition	Recruiting	Synthetic Biologics (formerly Adeona Pharmaceuticals)	Phase 2	2011-10-01	Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with cognition. Currently, there are no FDA-approved treatments targeting cognitive function in Multiple Sclerosis. This trial will ascertain whether treatment with an estrogen pill, used in combination with standard MS anti-inflammatory drugs, can improve cognitive testing as compared to treatment with a placebo pill in combination with standard anti-inflammatory drugs in women with MS.
NCT01466114 ↗	Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition	Recruiting	University of California, Los Angeles	Phase 2	2011-10-01	Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with cognition. Currently, there are no FDA-approved treatments targeting cognitive function in Multiple Sclerosis. This trial will ascertain whether treatment with an estrogen pill, used in combination with standard MS anti-inflammatory drugs, can improve cognitive testing as compared to treatment with a placebo pill in combination with standard anti-inflammatory drugs in women with MS.
NCT02980042 ↗	Safety of Switching From Rituximab to Ocrelizumab in MS Patients	Completed	University of Colorado, Denver	Phase 3	2017-01-01	This is a prospective between and within group observational study to determine differences in tolerability, immunogenicity and safety related outcomes for 100 multiple sclerosis (MS) patients who have been administered at least two infusions of rituximab, six months apart and are willing to be switched to ocrelizumab compared to a 100 patients who are continuing on rituximab as a comparison cohort from the clinic population treated as part of clinical care.
NCT03853746 ↗	Short-term B-cell Depletion in Relapsing Multiple Sclerosis	Active, not recruiting	National Multiple Sclerosis Society	Phase 4	2019-04-01	Several disease-modifying therapies (DMTs) have been shown to be effective in reducing the disease activity in patients with relapsing forms of multiple sclerosis (MS) but these treatments, often need to be used continuously for an unknown duration, rendering the long-term use extremely expensive. In addition, chronic administration of DMTs is often associated with undesirable side effects. Among these medications, B-cell depleting monoclonal antibodies might have the properties of an ideal group of medications: i) B-cell depleting antibodies have proven to be extremely potent in reducing or stopping the disease activity in relapsing MS, ii) B-cell depleting antibodies are very safe if used for a short period and use for a short duration may stop the inflammatory disease activity over long term, although current clinical practice and protocols are based on continuing B-cell depletion for an unknown period of time. Indeed, early phase clinical trials of rituximab and ocrelizumab suggested that a short course treatment with B-cell depleting antibodies can have long term effects and disease activity will not return even long after B-cell repopulation in the blood. This long-term effect might be related to the specific pattern of B-cell tolerance defect in patients with MS and the potential of its normalization with B-cell depleting antibodies. By analyzing the reactivity of recombinant antibodies expressed from single B-cells, the investigators' collaborators have demonstrated that the pattern of B-cell tolerance defect is different in people with MS who only display an impaired removal of developing autoreactive B-cells in the periphery while central B-cell tolerance in the bone marrow is functional in most patients. In contrast, patients with rheumatoid arthritis (RA), type-1 diabetes (T1D) or Sjögren's syndrome (SS) show defective central and peripheral B-cell tolerance checkpoints. As a consequence, while anti-B-cell therapy does not correct defective early B-cell tolerance checkpoints in T1D and only temporarily slows down autoimmune processes before newly generated autoreactive B-cells likely induce patient relapse, the investigators postulate that the efficacy of B-cell depleting antibodies in MS may be linked to the B-cell depleting antibodies' normal central B-cell tolerance and the production of a normal B-cell and T-cell compartment after anti-B-cell therapy. The investigators' goal is to provide proof-of-concept that a short duration of treatment with B-cell depleting antibodies can correct B-cell tolerance defects in MS and allow for medication-free prolonged freedom from disease activity, at least in a proportion of subjects with relapsing MS. In an open label study, 10 patients with active relapsing MS will be treated with two courses of ocrelizumab and will be followed clinically and radiologically for at least two and a half years. Time to the return of disease activity (defined as clinical relapses or new or enhancing lesions on the MRI) will be the primary outcome of the study. The investigators will harvest B-cells before starting the treatment and after B-cell repopulation and assess the central and peripheral tolerance defects. The investigators hypothesize that in most participants, the disease activity will not come back, and this prolonged response to anti cluster of differentiation 20 (CD-20) therapy is associated with normalization of B-cell tolerance defect in these patients. Considering the safety of this approach, it can be adopted widely among people with MS. Hence, the proposed B-cell analyses before and after B-cell depletion in people with MS will provide novel insights regarding the mechanisms underlying the beneficial effect of B-cell depleting antibodies and the potential long-term suppression of disease activity. This strategy can therefore improve the approach to treatment of many people with relapsing MS.

Clinical Trial Conditions for OCREVUS

Condition Name

Condition Name for OCREVUS
Intervention	Trials
Multiple Sclerosis	5
Secondary-progressive Multiple Sclerosis	2
Multiple Sclerosis, Relapsing-Remitting	2
Relapsing Multiple Sclerosis	2

Condition MeSH

Condition MeSH for OCREVUS
Intervention	Trials
Multiple Sclerosis	14
Sclerosis	13
Multiple Sclerosis, Relapsing-Remitting	6
Multiple Sclerosis, Chronic Progressive	5

Clinical Trial Locations for OCREVUS

Trials by Country

Trials by Country for OCREVUS
Location	Trials
United States	91
Ukraine	23
Russian Federation	22
Italy	20
Brazil	17

Trials by US State

Trials by US State for OCREVUS
Location	Trials
California	7
Texas	5
Colorado	5
Tennessee	4
Ohio	4

Clinical Trial Progress for OCREVUS

Clinical Trial Phase

Clinical Trial Phase for OCREVUS
Clinical Trial Phase	Trials
PHASE3	1
Phase 4	7
Phase 3	6

Clinical Trial Status

Clinical Trial Status for OCREVUS
Clinical Trial Phase	Trials
Recruiting	10
Active, not recruiting	2
Completed	2

Clinical Trial Sponsors for OCREVUS

Sponsor Name

Sponsor Name for OCREVUS
Sponsor	Trials
Hoffmann-La Roche	3
Genentech, Inc.	2
Johns Hopkins University	2

Sponsor Type

Sponsor Type for OCREVUS
Sponsor	Trials
Other	37
Industry	8
NIH	1

OCREVUS (ocrelizumab): Clinical Trials Update, Market Analysis, and 2030 Projection

Last updated: April 23, 2026

Summary: OCREVUS (ocrelizumab) is the market’s largest anti-CD20 therapy in multiple sclerosis (MS), with dominance anchored in the RRMS pivot from pivotal trials and expansion into PPMS after the ORATORIO dataset. In 2024, the label expanded via additional dosing-interval harmonization and operational uptake, while competitive pressure is rising from BTK and CD20-concurrent positioning, as well as newer entrant tolerability and dosing platforms. Near-term revenue remains supported by durable persistence, broad neurologist adoption, and payor familiarity, while mid-decade growth depends on ongoing use in expanded MS phenotypes, potential new combination and observational evidence, and competitive response cycles across biosimilars and alternative mechanisms.

---

What is OCREVUS and what does the MS label cover?

Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody delivered as intravenous infusion. In the US and EU, the core MS indication set includes:

• Relapsing forms of MS (RMS) including clinically isolated syndrome with MS features (US label phrasing varies by region), and active RRMS
• Primary progressive MS (PPMS) with active disease
• A broad real-world use case supports disease-modifying therapy (DMT) in relapsing and progressive disease domains

Mechanism constraint that shapes competition: anti-CD20 depletion drives B-cell reduction; the practical differentiation in the market is less about efficacy claims and more about infusion logistics, persistence, safety monitoring burden, and switching tolerance in a class where neurologists can switch between CD20 options on a predictable ramp.

Key clinical program anchoring (regulatory pivot):

• OPERA I/II (RRMS) and ORATORIO (PPMS) form the efficacy backbone for payor coverage and treatment guidelines. (Efficacy dataset described in EPAR and US prescribing information.) [1,2]

---

What clinical trial updates matter for OCREVUS now?

1) How is OCREVUS used in ongoing expansion studies and what endpoints track?

Recent Ocrevus clinical activity largely tracks these themes:

• Disease activity suppression in relapsing MS using MRI endpoints (new/enlarging T2 lesions, Gd-enhancing lesions)
• Disability progression metrics in PPMS and mixed progressive phenotypes, typically using confirmed disability progression time-to-event endpoints
• Safety and immune reconstitution parameters, including infection rates and hypogammaglobulinemia surveillance patterns
• Immunogenicity and B-cell kinetics in maintenance regimens, relevant to dosing interval strategies and potential future subcutaneous or reduced-infusion concepts (program lineage, not a new route change in the main label)

Operational reality: the market effect of trial readouts tends to be strongest when they support either (a) payor authorization persistence (treatment continuity), (b) a reduction in monitoring burden, or (c) inclusion of additional subpopulations that match existing clinician referral patterns.

2) What outcomes drive commercial confidence in the near term?

The commercial read-through from late-stage program lineage relies on:

• Consistent relapse reduction in RRMS (OPERA)
• Lower risk of disability progression in PPMS with active disease (ORATORIO) These are the claims that drive initial uptake and ongoing long-term persistence. (OPERA/ORATORIO trial summaries are documented in regulator-facing label materials.) [1,2]

3) What does the competitive landscape imply for future trial strategy?

BTK inhibition and newer immune modulation strategies create incentives for future Ocrevus-facing trials to emphasize:

• Lower infection risk and long-term safety durability
• Maintenance convenience versus multi-step induction/monitoring schedules from alternatives
• Switching outcomes for patients moving from other DMT classes

The market expects Ocrevus to hold its position through a mix of evidence generation and pragmatic real-world continuity rather than large mechanism shift.

---

How big is the OCREVUS market and what are the drivers?

Market sizing framework

For Ocrevus, the investable market is defined by:

• Diagnosed MS population eligible for DMT
• Share of CD20 class usage within RRMS and PPMS active disease subsets
• Persistence (treatment duration), driven by clinician preference and infusion network maturity
• Net price after rebates (not disclosed consistently across jurisdictions in one place)

Because public sources typically report US-only revenues and do not provide region-by-region net sales after rebates in one unified dataset, the most defensible commercial view uses issuer-reported net sales as the anchor and treats ex-US as an offset.

Key commercial drivers

1. Administration reliability and schedule predictability
   Ocrevus is administered as an IV infusion with a maintenance cadence that supports clinic scheduling and patient adherence.

2. Efficacy credibility in two clinical domains
   RRMS relapse control and PPMS progression control are the two pillars that keep treatment switching rates lower than for therapies with narrower indications. [1,2]

3. Safety familiarity
   Longstanding monitoring protocols for anti-CD20 therapy reduce clinician friction and payor barriers.

4. Real-world persistence
   Once established, anti-CD20 patients tend to remain on therapy through multiple annual cycles unless contraindications emerge.

---

What are the latest market performance signals and how does competition affect them?

Competition: where Ocrevus faces pressure

• Other anti-CD20 therapies with different administration profiles and regional biosimilar dynamics
• Non-CD20 immune therapies, including BTK inhibitors and other mechanisms, that can shift neurologist choice by convenience or perceived safety tradeoffs
• Oral therapies that reduce infusion burden and can capture adherence-sensitive patients

Competitive effects by decision point

• New starts: Ocrevus is increasingly evaluated against oral options and other immune strategies. Choice hinges on risk tolerance, monitoring capacity, and patient preference.
• Switches: switch decisions cluster around infection history, comorbidities, and insurance dynamics.
• Persistence: Ocrevus persistence remains strong where infusion infrastructure exists and patients tolerate anti-CD20 safety monitoring.

Market narrative consistency

Ocrevus has remained a core “baseline” MS DMT in the CD20 class since regulatory acceptance for RRMS and PPMS domains. [1,2]

---

2030 projection: revenue path, scenario logic, and key assumptions

Scenario structure

Projection is organized into three scenarios based on:

• New patient penetration
• Persistence (drop-off from switches and discontinuation)
• Net price pressure from competition and policy tightening
• Regional expansion or stabilization

Base case (most probable)

• Growth rate: low single-digit to mid single-digit annually through 2027, then moderating to mid single-digit into 2030 driven by persistence offsetting competitive inroads.
• Key offsets: continued neurologist adoption, stable dosing logistics, and long-term efficacy credibility.

Upside case

• Higher persistence due to stronger real-world safety evidence and smoother immune reconstitution management
• Improved access through clinic network expansion and payor contracting
• Incremental label positioning through additional MS subpopulation evidence

Downside case

• Faster share loss to non-CD20 oral competitors
• Higher discontinuation due to safety-managed immune complications
• Net price compression and contracting pressure from anti-CD20 peers and biosimilar entry

Projected share drivers to 2030

• Persisting dominance in progressive RRMS-to-PPMS transition strategy: anti-CD20 remains a stable option in progressive disease with active features.
• Reduced differentiation pressure from “efficacy saturation”: as multiple MS agents show similar MRI control in trials, decision points shift toward convenience and safety protocols.

---

What are the measurable business KPIs to track for OCREVUS?

Clinical-to-commercial KPIs

• MRI lesion control consistency in post-marketing datasets (proxy for clinician confidence)
• Confirmed disability progression rates in relevant subgroups (proxy for long-term payor retention)
• Infections and hypogammaglobulinemia incidence trends (proxy for safety-driven switching)
• Treatment discontinuation rates and restart patterns (proxy for persistence)

Market KPIs

• New-start counts by quarter in RMS and PPMS-active cohorts
• Share of CD20 class within newly treated MS patients
• Net sales trend vs. peers (if issuer data provides segment breakdowns)
• Contracting and payer utilization changes tied to infusion center access

---

Key Takeaways

• OCREVUS is anchored by the OPERA (RRMS) and ORATORIO (PPMS) efficacy evidence and remains a leading anti-CD20 DMT across relapsing and active progressive MS. [1,2]
• The immediate clinical-trial impact is less about first-in-class efficacy shifts and more about safety durability, immune reconstitution and monitoring optimization, and subgroup evidence that protects continuation.
• Market growth to 2030 is persistence-led: competitive share losses can be offset by stable clinic infrastructure, payor familiarity, and long-term confidence in disability outcomes for eligible patients.
• The decisive variables for revenue trajectory are net price pressure, discontinuation/switch rates, and penetration in newly treated cohorts against oral and alternative immune therapies.

---

FAQs

1) Does OCREVUS cover both relapsing and primary progressive MS?

Yes. Ocrelizumab has indications spanning relapsing forms of MS and primary progressive MS with active disease, based on OPERA and ORATORIO clinical evidence described in regulatory label materials. [1,2]

2) What endpoints drive continued payor support for OCREVUS?

For MS DMTs, the endpoints that matter most commercially are MRI disease activity control (new/enlarging lesions and enhancement) and disability progression endpoints (confirmed disability progression), supported by the pivotal evidence base. [1,2]

3) What is the main commercial threat to OCREVUS?

Therapy-switch risk driven by convenience (oral options) and alternative mechanisms with differentiated safety-management narratives, plus net price pressure from competitive contracting and class competitors.

4) What KPI best predicts OCREVUS revenue durability?

Persistence: discontinuation and switch rates after initial initiation, plus new-start penetration in RMS and PPMS-active subgroups.

5) How will clinical trial updates most likely affect near-term OCREVUS sales?

When readouts tighten the safety-monitoring playbook and improve long-term tolerability in real-world monitoring, they reduce switching friction and support continuation.

---

References

[1] European Medicines Agency. Ocrevus EPAR: Product information and assessment summary. EMA.
[2] US Food and Drug Administration. Ocrevus (ocrelizumab) prescribing information. FDA.